Business Context and Reporting Period
This Form 8-K, filed on October 18, 2023, reports on events occurring on October 17, 2023, for Data Knights Acquisition Corp. (DKDC). The filing details the results of a Special Meeting of Stockholders held to approve a business combination with OneMedNet, a Delaware corporation. The meeting was conducted in lieu of the 2023 annual meeting.
Key Financial Metrics and Liquidity
The filing does not provide standard operating financial metrics such as revenue, profit, or cash flow for the reporting period, as the primary focus is the corporate transaction. However, specific liquidity data regarding the Trust Account is disclosed:
- Redemption Activity: 1,614,148 shares of Class A Common Stock were redeemed.
- Funds Removed: Approximately $17.9 million was withdrawn from the Trust Account to pay redeeming stockholders.
- Redemption Price: Approximately $11.12 per share.
- Remaining Trust Balance: Approximately $1.1 million remains in the Trust Account post-redemption.
Material Changes and Voting Results
Stockholders approved seven proposals necessary to consummate the Business Combination. As of the record date (September 20, 2023), 5,172,973 shares were outstanding, with 4,690,565 shares represented at the meeting.
- Proposal 1 (NTA Amendment): Approved to remove the $5,000,000 net tangible asset limitation. (For: 4,590,735; Against: 5,562).
- Proposal 2 (Merger Agreement): Approved the Business Combination with OneMedNet. (For: 4,680,323; Against: 10,242).
- Proposal 3 (Nasdaq Listing): Approved issuance of >20% of common stock and change in control. (For: 4,680,323; Against: 10,242).
- Proposal 4 (Charter Amendment): Approved the Third Amended and Restated Certificate of Incorporation, including supermajority voting requirements for future amendments. (For: 4,520,354; Against: 170,211).
- Proposal 5 (Director Election): Elected eight directors to the post-combination board. Most directors received near-unanimous support; Dr. Jeffrey Yu received 4,525,916 votes For and 164,649 Withheld.
- Proposal 6 (Equity Incentive Plan): Approved the 2022 Equity Incentive Plan. (For: 4,520,354; Against: 170,211).
- Proposal 7 (Adjournment): Approved the right to adjourn the meeting if necessary. (For: 4,680,323; Against: 10,242).
Outlook, Risks, and Contingencies
The filing includes extensive forward-looking statements regarding the anticipated growth of OneMedNet and the completion of the Business Combination. Management highlights several material risks that could cause actual results to differ from projections:
- Closing Risks: The transaction may not be completed in a timely manner or at all, potentially affecting security prices.
- Regulatory and Listing: Risks regarding the ability to meet stock exchange listing standards post-combination and changes in applicable laws.
- Operational Disruption: Potential diversion of management attention and disruption to OneMedNet's ongoing operations.
- Financial Uncertainty: Risks related to OneMedNet's expense estimates, profitability projections, and the impact of economic factors such as rising interest rates.
- Valuation: The filing notes a lack of a third-party valuation in the decision to pursue the combination.
Investor Verification Checklist
- Verify the final closing date of the Business Combination and confirm the post-merger ticker symbol.
- Confirm the exact remaining cash balance in the Trust Account ($1.1 million) and its sufficiency for post-merger operations.
- Review the Definitive Proxy Statement (filed September 21, 2023) for detailed financial projections of OneMedNet not included in this 8-K.
- Monitor the composition of the new Board of Directors and the terms of the 2022 Equity Incentive Plan.
- Assess the impact of the significant share redemption (approx. 31% of outstanding shares) on the company's capital structure.